APO Research
Talk to an analyst

APO RESEARCH · REPORT

Exocrine Pancreatic Insufficiency Therapeutic

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Exocrine Pancreatic Insufficiency Therapeutic Market Analysis and Forecast 2026-2032

2 January 2026191 pages

Choose your research edition.

Industry ResearchExocrine Pancreatic Insufficiency Therapeutic Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Exocrine Pancreatic Insufficiency Therapeutic Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal Exocrine Pancreatic Insufficiency Therapeutic Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Exocrine Pancreatic Insufficiency Therapeutic Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Exocrine Pancreatic Insufficiency Therapeutic Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Exocrine Pancreatic Insufficiency Therapeutic market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Exocrine Pancreatic Insufficiency Therapeutic is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Exocrine Pancreatic Insufficiency Therapeutic is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Exocrine Pancreatic Insufficiency Therapeutic is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Exocrine Pancreatic Insufficiency Therapeutic is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Exocrine Pancreatic Insufficiency Therapeutic include Janssen Pharmaceuticals, AbbVie, CHIESI Farmaceutici S.p.A., AzurRx and Allergan, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Exocrine Pancreatic Insufficiency Therapeutic, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Exocrine Pancreatic Insufficiency Therapeutic, also provides the revenue of main regions and countries. Of the upcoming market potential for Exocrine Pancreatic Insufficiency Therapeutic, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Exocrine Pancreatic Insufficiency Therapeutic revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Exocrine Pancreatic Insufficiency Therapeutic market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Exocrine Pancreatic Insufficiency Therapeutic revenue, projected growth trends, production technology, application and end-user industry.

Exocrine Pancreatic Insufficiency Therapeutic Segment by Company

Janssen Pharmaceuticals

AbbVie

CHIESI Farmaceutici S.p.A.

AzurRx

Allergan

Exocrine Pancreatic Insufficiency Therapeutic Segment by Type

Pancreatic Enzyme Replacement Therapy

Nutritional Therapy

Exocrine Pancreatic Insufficiency Therapeutic Segment by Application

Hospital Pharmacies

Retail Pharmacies & Drug Stores

Others

Exocrine Pancreatic Insufficiency Therapeutic Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Exocrine Pancreatic Insufficiency Therapeutic market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Exocrine Pancreatic Insufficiency Therapeutic and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Exocrine Pancreatic Insufficiency Therapeutic.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Exocrine Pancreatic Insufficiency Therapeutic in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Exocrine Pancreatic Insufficiency Therapeutic company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Exocrine Pancreatic Insufficiency Therapeutic revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Exocrine Pancreatic Insufficiency Therapeutic Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Pancreatic Enzyme Replacement Therapy Major Player Table 3. Nutritional Therapy Major Player Table 4. Global Exocrine Pancreatic Insufficiency Therapeutic Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospital Pharmacies Major Player Table 6. Retail Pharmacies & Drug Stores Major Player Table 7. Others Major Player Table 8. Exocrine Pancreatic Insufficiency Therapeutic Industry Trends Table 9. Exocrine Pancreatic Insufficiency Therapeutic Industry Drivers Table 10. Exocrine Pancreatic Insufficiency Therapeutic Industry Opportunities and Challenges Table 11. Exocrine Pancreatic Insufficiency Therapeutic Industry Restraints Table 12. Global Exocrine Pancreatic Insufficiency Therapeutic Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Exocrine Pancreatic Insufficiency Therapeutic Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Exocrine Pancreatic Insufficiency Therapeutic Market Share by Region (2021-2026) Table 15. Global Exocrine Pancreatic Insufficiency Therapeutic Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Exocrine Pancreatic Insufficiency Therapeutic Market Share by Region (2027-2032) Table 17. Global Exocrine Pancreatic Insufficiency Therapeutic Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Exocrine Pancreatic Insufficiency Therapeutic Revenue Market Share by Players (2021-2026) Table 19. Global Exocrine Pancreatic Insufficiency Therapeutic Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Exocrine Pancreatic Insufficiency Therapeutic Key Players Headquarters & Area Served Table 21. Global Exocrine Pancreatic Insufficiency Therapeutic Players, Product Type & Application Table 22. Global Exocrine Pancreatic Insufficiency Therapeutic Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Exocrine Pancreatic Insufficiency Therapeutic by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Exocrine Pancreatic Insufficiency Therapeutic Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Exocrine Pancreatic Insufficiency Therapeutic Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Exocrine Pancreatic Insufficiency Therapeutic Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Exocrine Pancreatic Insufficiency Therapeutic Revenue Market Share by Type (2021-2026) Table 29. Global Exocrine Pancreatic Insufficiency Therapeutic Revenue Market Share by Type (2027-2032) Table 30. Global Exocrine Pancreatic Insufficiency Therapeutic Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Exocrine Pancreatic Insufficiency Therapeutic Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Exocrine Pancreatic Insufficiency Therapeutic Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Exocrine Pancreatic Insufficiency Therapeutic Revenue Market Share by Application (2021-2026) Table 34. Global Exocrine Pancreatic Insufficiency Therapeutic Revenue Market Share by Application (2027-2032) Table 35. Janssen Pharmaceuticals Company Information Table 36. Janssen Pharmaceuticals Business Overview Table 37. Janssen Pharmaceuticals Exocrine Pancreatic Insufficiency Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Janssen Pharmaceuticals Exocrine Pancreatic Insufficiency Therapeutic Product Portfolio Table 39. Janssen Pharmaceuticals Recent Development Table 40. AbbVie Company Information Table 41. AbbVie Business Overview Table 42. AbbVie Exocrine Pancreatic Insufficiency Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. AbbVie Exocrine Pancreatic Insufficiency Therapeutic Product Portfolio Table 44. AbbVie Recent Development Table 45. CHIESI Farmaceutici S.p.A. Company Information Table 46. CHIESI Farmaceutici S.p.A. Business Overview Table 47. CHIESI Farmaceutici S.p.A. Exocrine Pancreatic Insufficiency Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. CHIESI Farmaceutici S.p.A. Exocrine Pancreatic Insufficiency Therapeutic Product Portfolio Table 49. CHIESI Farmaceutici S.p.A. Recent Development Table 50. AzurRx Company Information Table 51. AzurRx Business Overview Table 52. AzurRx Exocrine Pancreatic Insufficiency Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. AzurRx Exocrine Pancreatic Insufficiency Therapeutic Product Portfolio Table 54. AzurRx Recent Development Table 55. Allergan Company Information Table 56. Allergan Business Overview Table 57. Allergan Exocrine Pancreatic Insufficiency Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Allergan Exocrine Pancreatic Insufficiency Therapeutic Product Portfolio Table 59. Allergan Recent Development Table 60. North America Exocrine Pancreatic Insufficiency Therapeutic Revenue by Type (2021-2026) & (US$ Million) Table 61. North America Exocrine Pancreatic Insufficiency Therapeutic Revenue by Type (2027-2032) & (US$ Million) Table 62. North America Exocrine Pancreatic Insufficiency Therapeutic Revenue by Application (2021-2026) & (US$ Million) Table 63. North America Exocrine Pancreatic Insufficiency Therapeutic Revenue by Application (2027-2032) & (US$ Million) Table 64. North America Exocrine Pancreatic Insufficiency Therapeutic Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 65. North America Exocrine Pancreatic Insufficiency Therapeutic Revenue by Country (2021-2026) & (US$ Million) Table 66. North America Exocrine Pancreatic Insufficiency Therapeutic Revenue by Country (US$ Million) & (2027-2032) Table 67. Europe Exocrine Pancreatic Insufficiency Therapeutic Revenue by Type (2021-2026) & (US$ Million) Table 68. Europe Exocrine Pancreatic Insufficiency Therapeutic Revenue by Type (2027-2032) & (US$ Million) Table 69. Europe Exocrine Pancreatic Insufficiency Therapeutic Revenue by Application (2021-2026) & (US$ Million) Table 70. Europe Exocrine Pancreatic Insufficiency Therapeutic Revenue by Application (2027-2032) & (US$ Million) Table 71. Europe Exocrine Pancreatic Insufficiency Therapeutic Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 72. Europe Exocrine Pancreatic Insufficiency Therapeutic Revenue by Country (2021-2026) & (US$ Million) Table 73. Europe Exocrine Pancreatic Insufficiency Therapeutic Revenue by Country (US$ Million) & (2027-2032) Table 74. China Exocrine Pancreatic Insufficiency Therapeutic Revenue by Type (2021-2026) & (US$ Million) Table 75. China Exocrine Pancreatic Insufficiency Therapeutic Revenue by Type (2027-2032) & (US$ Million) Table 76. China Exocrine Pancreatic Insufficiency Therapeutic Revenue by Application (2021-2026) & (US$ Million) Table 77. China Exocrine Pancreatic Insufficiency Therapeutic Revenue by Application (2027-2032) & (US$ Million) Table 78. Asia Exocrine Pancreatic Insufficiency Therapeutic Revenue by Type (2021-2026) & (US$ Million) Table 79. Asia Exocrine Pancreatic Insufficiency Therapeutic Revenue by Type (2027-2032) & (US$ Million) Table 80. Asia Exocrine Pancreatic Insufficiency Therapeutic Revenue by Application (2021-2026) & (US$ Million) Table 81. Asia Exocrine Pancreatic Insufficiency Therapeutic Revenue by Application (2027-2032) & (US$ Million) Table 82. Asia Exocrine Pancreatic Insufficiency Therapeutic Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 83. Asia Exocrine Pancreatic Insufficiency Therapeutic Revenue by Region (US$ Million) & (2021-2026) Table 84. Asia Exocrine Pancreatic Insufficiency Therapeutic Revenue by Region (US$ Million) & (2027-2032) Table 85. SAMEA Exocrine Pancreatic Insufficiency Therapeutic Revenue by Type (2021-2026) & (US$ Million) Table 86. SAMEA Exocrine Pancreatic Insufficiency Therapeutic Revenue by Type (2027-2032) & (US$ Million) Table 87. SAMEA Exocrine Pancreatic Insufficiency Therapeutic Revenue by Application (2021-2026) & (US$ Million) Table 88. SAMEA Exocrine Pancreatic Insufficiency Therapeutic Revenue by Application (2027-2032) & (US$ Million) Table 89. SAMEA Exocrine Pancreatic Insufficiency Therapeutic Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 90. SAMEA Exocrine Pancreatic Insufficiency Therapeutic Revenue by Country (2021-2026) & (US$ Million) Table 91. SAMEA Exocrine Pancreatic Insufficiency Therapeutic Revenue by Country (US$ Million) & (2027-2032) Table 92. Research Programs/Design for This Report Table 93. Authors List of This Report Table 94. Secondary Sources Table 95. Primary Sources List of Figures Figure 1. Exocrine Pancreatic Insufficiency Therapeutic Image Figure 2. Global Exocrine Pancreatic Insufficiency Therapeutic Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Exocrine Pancreatic Insufficiency Therapeutic Market Size Share 2021 VS 2025 VS 2032 Figure 4. Pancreatic Enzyme Replacement Therapy Image Figure 5. Nutritional Therapy Image Figure 6. Global Exocrine Pancreatic Insufficiency Therapeutic Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Exocrine Pancreatic Insufficiency Therapeutic Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospital Pharmacies Image Figure 9. Retail Pharmacies & Drug Stores Image Figure 10. Others Image Figure 11. Global Exocrine Pancreatic Insufficiency Therapeutic Market Size (US$ Million) & (2021-2032) Figure 12. Global Exocrine Pancreatic Insufficiency Therapeutic Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Exocrine Pancreatic Insufficiency Therapeutic Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Exocrine Pancreatic Insufficiency Therapeutic Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Exocrine Pancreatic Insufficiency Therapeutic Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Exocrine Pancreatic Insufficiency Therapeutic Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Exocrine Pancreatic Insufficiency Therapeutic Revenue Market Share by Type (2021-2032) Figure 19. Global Exocrine Pancreatic Insufficiency Therapeutic Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Exocrine Pancreatic Insufficiency Therapeutic Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Exocrine Pancreatic Insufficiency Therapeutic Revenue Market Share by Application (2021-2032) Figure 22. North America Exocrine Pancreatic Insufficiency Therapeutic Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Exocrine Pancreatic Insufficiency Therapeutic Revenue Share by Type (2021-2032) Figure 24. North America Exocrine Pancreatic Insufficiency Therapeutic Revenue Share by Application (2021-2032) Figure 25. North America Exocrine Pancreatic Insufficiency Therapeutic Revenue Share by Country (2021-2032) Figure 26. United States Exocrine Pancreatic Insufficiency Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Exocrine Pancreatic Insufficiency Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Exocrine Pancreatic Insufficiency Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Exocrine Pancreatic Insufficiency Therapeutic Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Exocrine Pancreatic Insufficiency Therapeutic Revenue Share by Type (2021-2032) Figure 31. Europe Exocrine Pancreatic Insufficiency Therapeutic Revenue Share by Application (2021-2032) Figure 32. Europe Exocrine Pancreatic Insufficiency Therapeutic Revenue Share by Country (2021-2032) Figure 33. Germany Exocrine Pancreatic Insufficiency Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Exocrine Pancreatic Insufficiency Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Exocrine Pancreatic Insufficiency Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Exocrine Pancreatic Insufficiency Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Exocrine Pancreatic Insufficiency Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Exocrine Pancreatic Insufficiency Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Exocrine Pancreatic Insufficiency Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Exocrine Pancreatic Insufficiency Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Exocrine Pancreatic Insufficiency Therapeutic Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Exocrine Pancreatic Insufficiency Therapeutic Revenue Share by Type (2021-2032) Figure 43. China Exocrine Pancreatic Insufficiency Therapeutic Revenue Share by Application (2021-2032) Figure 44. Asia Exocrine Pancreatic Insufficiency Therapeutic Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Exocrine Pancreatic Insufficiency Therapeutic Revenue Share by Type (2021-2032) Figure 46. Asia Exocrine Pancreatic Insufficiency Therapeutic Revenue Share by Application (2021-2032) Figure 47. Asia Exocrine Pancreatic Insufficiency Therapeutic Revenue Share by Region (2021-2032) Figure 48. Japan Exocrine Pancreatic Insufficiency Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Exocrine Pancreatic Insufficiency Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Exocrine Pancreatic Insufficiency Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Exocrine Pancreatic Insufficiency Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Exocrine Pancreatic Insufficiency Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Exocrine Pancreatic Insufficiency Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Exocrine Pancreatic Insufficiency Therapeutic Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Exocrine Pancreatic Insufficiency Therapeutic Revenue Share by Type (2021-2032) Figure 56. SAMEA Exocrine Pancreatic Insufficiency Therapeutic Revenue Share by Application (2021-2032) Figure 57. SAMEA Exocrine Pancreatic Insufficiency Therapeutic Revenue Share by Country (2021-2032) Figure 58. Brazil Exocrine Pancreatic Insufficiency Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Exocrine Pancreatic Insufficiency Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Exocrine Pancreatic Insufficiency Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Exocrine Pancreatic Insufficiency Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Exocrine Pancreatic Insufficiency Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Exocrine Pancreatic Insufficiency Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Exocrine Pancreatic Insufficiency Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Exocrine Pancreatic Insufficiency Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Exocrine Pancreatic Insufficiency Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Exocrine Pancreatic Insufficiency Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Exocrine Pancreatic Insufficiency Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Pancreatic Enzyme Replacement Therapy
  • Nutritional Therapy
Applications
  • Hospital Pharmacies
  • Retail Pharmacies & Drug Stores
  • Others
Companies covered
  • Janssen Pharmaceuticals
  • AbbVie
  • CHIESI Farmaceutici S.p.A.
  • AzurRx
  • Allergan

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Exocrine Pancreatic Insufficiency Therapeutic Market by Type
  3. 1.2.1 Global Exocrine Pancreatic Insufficiency Therapeutic Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Pancreatic Enzyme Replacement Therapy
  5. 1.2.3 Nutritional Therapy
  6. 1.3 Exocrine Pancreatic Insufficiency Therapeutic Market by Application
  7. 1.3.1 Global Exocrine Pancreatic Insufficiency Therapeutic Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital Pharmacies
  9. 1.3.3 Retail Pharmacies & Drug Stores
  10. 1.3.4 Others
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Exocrine Pancreatic Insufficiency Therapeutic Market Dynamics
  1. 2.1 Exocrine Pancreatic Insufficiency Therapeutic Industry Trends
  2. 2.2 Exocrine Pancreatic Insufficiency Therapeutic Industry Drivers
  3. 2.3 Exocrine Pancreatic Insufficiency Therapeutic Industry Opportunities and Challenges
  4. 2.4 Exocrine Pancreatic Insufficiency Therapeutic Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Exocrine Pancreatic Insufficiency Therapeutic Market Perspective (2021-2032)
  2. 3.2 Global Exocrine Pancreatic Insufficiency Therapeutic Growth Trends by Region
  3. 3.2.1 Global Exocrine Pancreatic Insufficiency Therapeutic Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Exocrine Pancreatic Insufficiency Therapeutic Market Size by Region (2021-2026)
  5. 3.2.3 Global Exocrine Pancreatic Insufficiency Therapeutic Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Exocrine Pancreatic Insufficiency Therapeutic Revenue by Players
  2. 4.1.1 Global Exocrine Pancreatic Insufficiency Therapeutic Revenue by Players (2021-2026)
  3. 4.1.2 Global Exocrine Pancreatic Insufficiency Therapeutic Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Exocrine Pancreatic Insufficiency Therapeutic Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Exocrine Pancreatic Insufficiency Therapeutic Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Exocrine Pancreatic Insufficiency Therapeutic Key Players Headquarters & Area Served
  7. 4.4 Global Exocrine Pancreatic Insufficiency Therapeutic Players, Product Type & Application
  8. 4.5 Global Exocrine Pancreatic Insufficiency Therapeutic Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Exocrine Pancreatic Insufficiency Therapeutic Market CR5 and HHI
  11. 4.6.3 2025 Exocrine Pancreatic Insufficiency Therapeutic Tier 1, Tier 2, and Tier 3
5 Exocrine Pancreatic Insufficiency Therapeutic Market Size by Type
  1. 5.1 Global Exocrine Pancreatic Insufficiency Therapeutic Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Exocrine Pancreatic Insufficiency Therapeutic Revenue by Type (2021-2032)
  3. 5.3 Global Exocrine Pancreatic Insufficiency Therapeutic Revenue Market Share by Type (2021-2032)
6 Exocrine Pancreatic Insufficiency Therapeutic Market Size by Application
  1. 6.1 Global Exocrine Pancreatic Insufficiency Therapeutic Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Exocrine Pancreatic Insufficiency Therapeutic Revenue by Application (2021-2032)
  3. 6.3 Global Exocrine Pancreatic Insufficiency Therapeutic Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Janssen Pharmaceuticals
  2. 7.1.1 Janssen Pharmaceuticals Company Information
  3. 7.1.2 Janssen Pharmaceuticals Business Overview
  4. 7.1.3 Janssen Pharmaceuticals Exocrine Pancreatic Insufficiency Therapeutic Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Janssen Pharmaceuticals Exocrine Pancreatic Insufficiency Therapeutic Product Portfolio
  6. 7.1.5 Janssen Pharmaceuticals Recent Developments
  7. 7.2 AbbVie
  8. 7.2.1 AbbVie Company Information
  9. 7.2.2 AbbVie Business Overview
  10. 7.2.3 AbbVie Exocrine Pancreatic Insufficiency Therapeutic Revenue and Gross Margin (2021-2026)
  11. 7.2.4 AbbVie Exocrine Pancreatic Insufficiency Therapeutic Product Portfolio
  12. 7.2.5 AbbVie Recent Developments
  13. 7.3 CHIESI Farmaceutici S.p.A.
  14. 7.3.1 CHIESI Farmaceutici S.p.A. Company Information
  15. 7.3.2 CHIESI Farmaceutici S.p.A. Business Overview
  16. 7.3.3 CHIESI Farmaceutici S.p.A. Exocrine Pancreatic Insufficiency Therapeutic Revenue and Gross Margin (2021-2026)
  17. 7.3.4 CHIESI Farmaceutici S.p.A. Exocrine Pancreatic Insufficiency Therapeutic Product Portfolio
  18. 7.3.5 CHIESI Farmaceutici S.p.A. Recent Developments
  19. 7.4 AzurRx
  20. 7.4.1 AzurRx Company Information
  21. 7.4.2 AzurRx Business Overview
  22. 7.4.3 AzurRx Exocrine Pancreatic Insufficiency Therapeutic Revenue and Gross Margin (2021-2026)
  23. 7.4.4 AzurRx Exocrine Pancreatic Insufficiency Therapeutic Product Portfolio
  24. 7.4.5 AzurRx Recent Developments
  25. 7.5 Allergan
  26. 7.5.1 Allergan Company Information
  27. 7.5.2 Allergan Business Overview
  28. 7.5.3 Allergan Exocrine Pancreatic Insufficiency Therapeutic Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Allergan Exocrine Pancreatic Insufficiency Therapeutic Product Portfolio
  30. 7.5.5 Allergan Recent Developments
8 North America
  1. 8.1 North America Exocrine Pancreatic Insufficiency Therapeutic Revenue (2021-2032)
  2. 8.2 North America Exocrine Pancreatic Insufficiency Therapeutic Revenue by Type (2021-2032)
  3. 8.2.1 North America Exocrine Pancreatic Insufficiency Therapeutic Revenue by Type (2021-2026)
  4. 8.2.2 North America Exocrine Pancreatic Insufficiency Therapeutic Revenue by Type (2027-2032)
  5. 8.3 North America Exocrine Pancreatic Insufficiency Therapeutic Revenue Share by Type (2021-2032)
  6. 8.4 North America Exocrine Pancreatic Insufficiency Therapeutic Revenue by Application (2021-2032)
  7. 8.4.1 North America Exocrine Pancreatic Insufficiency Therapeutic Revenue by Application (2021-2026)
  8. 8.4.2 North America Exocrine Pancreatic Insufficiency Therapeutic Revenue by Application (2027-2032)
  9. 8.5 North America Exocrine Pancreatic Insufficiency Therapeutic Revenue Share by Application (2021-2032)
  10. 8.6 North America Exocrine Pancreatic Insufficiency Therapeutic Revenue by Country
  11. 8.6.1 North America Exocrine Pancreatic Insufficiency Therapeutic Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Exocrine Pancreatic Insufficiency Therapeutic Revenue by Country (2021-2026)
  13. 8.6.3 North America Exocrine Pancreatic Insufficiency Therapeutic Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Exocrine Pancreatic Insufficiency Therapeutic Revenue (2021-2032)
  2. 9.2 Europe Exocrine Pancreatic Insufficiency Therapeutic Revenue by Type (2021-2032)
  3. 9.2.1 Europe Exocrine Pancreatic Insufficiency Therapeutic Revenue by Type (2021-2026)
  4. 9.2.2 Europe Exocrine Pancreatic Insufficiency Therapeutic Revenue by Type (2027-2032)
  5. 9.3 Europe Exocrine Pancreatic Insufficiency Therapeutic Revenue Share by Type (2021-2032)
  6. 9.4 Europe Exocrine Pancreatic Insufficiency Therapeutic Revenue by Application (2021-2032)
  7. 9.4.1 Europe Exocrine Pancreatic Insufficiency Therapeutic Revenue by Application (2021-2026)
  8. 9.4.2 Europe Exocrine Pancreatic Insufficiency Therapeutic Revenue by Application (2027-2032)
  9. 9.5 Europe Exocrine Pancreatic Insufficiency Therapeutic Revenue Share by Application (2021-2032)
  10. 9.6 Europe Exocrine Pancreatic Insufficiency Therapeutic Revenue by Country
  11. 9.6.1 Europe Exocrine Pancreatic Insufficiency Therapeutic Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Exocrine Pancreatic Insufficiency Therapeutic Revenue by Country (2021-2026)
  13. 9.6.3 Europe Exocrine Pancreatic Insufficiency Therapeutic Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Exocrine Pancreatic Insufficiency Therapeutic Revenue (2021-2032)
  2. 10.2 China Exocrine Pancreatic Insufficiency Therapeutic Revenue by Type (2021-2032)
  3. 10.2.1 China Exocrine Pancreatic Insufficiency Therapeutic Revenue by Type (2021-2026)
  4. 10.2.2 China Exocrine Pancreatic Insufficiency Therapeutic Revenue by Type (2027-2032)
  5. 10.3 China Exocrine Pancreatic Insufficiency Therapeutic Revenue Share by Type (2021-2032)
  6. 10.4 China Exocrine Pancreatic Insufficiency Therapeutic Revenue by Application (2021-2032)
  7. 10.4.1 China Exocrine Pancreatic Insufficiency Therapeutic Revenue by Application (2021-2026)
  8. 10.4.2 China Exocrine Pancreatic Insufficiency Therapeutic Revenue by Application (2027-2032)
  9. 10.5 China Exocrine Pancreatic Insufficiency Therapeutic Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Exocrine Pancreatic Insufficiency Therapeutic Revenue (2021-2032)
  2. 11.2 Asia Exocrine Pancreatic Insufficiency Therapeutic Revenue by Type (2021-2032)
  3. 11.2.1 Asia Exocrine Pancreatic Insufficiency Therapeutic Revenue by Type (2021-2026)
  4. 11.2.2 Asia Exocrine Pancreatic Insufficiency Therapeutic Revenue by Type (2027-2032)
  5. 11.3 Asia Exocrine Pancreatic Insufficiency Therapeutic Revenue Share by Type (2021-2032)
  6. 11.4 Asia Exocrine Pancreatic Insufficiency Therapeutic Revenue by Application (2021-2032)
  7. 11.4.1 Asia Exocrine Pancreatic Insufficiency Therapeutic Revenue by Application (2021-2026)
  8. 11.4.2 Asia Exocrine Pancreatic Insufficiency Therapeutic Revenue by Application (2027-2032)
  9. 11.5 Asia Exocrine Pancreatic Insufficiency Therapeutic Revenue Share by Application (2021-2032)
  10. 11.6 Asia Exocrine Pancreatic Insufficiency Therapeutic Revenue by Country
  11. 11.6.1 Asia Exocrine Pancreatic Insufficiency Therapeutic Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Exocrine Pancreatic Insufficiency Therapeutic Revenue by Country (2021-2026)
  13. 11.6.3 Asia Exocrine Pancreatic Insufficiency Therapeutic Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Exocrine Pancreatic Insufficiency Therapeutic Revenue (2021-2032)
  2. 12.2 SAMEA Exocrine Pancreatic Insufficiency Therapeutic Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Exocrine Pancreatic Insufficiency Therapeutic Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Exocrine Pancreatic Insufficiency Therapeutic Revenue by Type (2027-2032)
  5. 12.3 SAMEA Exocrine Pancreatic Insufficiency Therapeutic Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Exocrine Pancreatic Insufficiency Therapeutic Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Exocrine Pancreatic Insufficiency Therapeutic Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Exocrine Pancreatic Insufficiency Therapeutic Revenue by Application (2027-2032)
  9. 12.5 SAMEA Exocrine Pancreatic Insufficiency Therapeutic Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Exocrine Pancreatic Insufficiency Therapeutic Revenue by Country
  11. 12.6.1 SAMEA Exocrine Pancreatic Insufficiency Therapeutic Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Exocrine Pancreatic Insufficiency Therapeutic Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Exocrine Pancreatic Insufficiency Therapeutic Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst